Can food antigen exposure or intestinal barrier irritation raise fecal secretory IgA without elevating calprotectin or stool white blood cells?

Clinical evidence

• Distinct Biomarker Roles: Fecal secretory IgA (sIgA) acts as the primary mediator of the gut's adaptive immune defense, reflecting active mucosal surveillance and immune exclusion. Conversely, fecal calprotectin and stool white blood cells serve as direct, quantitative markers of neutrophil-driven innate inflammation and mucosal tissue damage.
• Functional Dissociation: Exposure to dietary antigens or mild, non-invasive mucosal irritation stimulates gut-associated lymphoid tissue to upregulate sIgA production. Because this adaptive response often resolves or neutralizes luminal challenges without triggering extensive tissue damage, it does not recruit the neutrophils required to elevate fecal calprotectin or stool white blood cell counts.

Mechanistic explanations

• Immune Exclusion: Upon encountering food antigens or experiencing barrier irritation, plasma cells in the lamina propria synthesize dimeric IgA, which is transported across epithelial cells into the lumen as sIgA. This antibody binds and neutralizes antigens, preventing them from penetrating the epithelial barrier.
• Prevention of Neutrophil Recruitment: By successfully binding luminal antigens, sIgA limits mucosal penetration. This prevents the activation of downstream inflammatory pathways that would otherwise release chemotactic signals to recruit neutrophils.
• Marker Separation: Calprotectin is heavily concentrated in neutrophil cytosol and only enters the stool when active, invasive inflammation damages the mucosal barrier. Consequently, successful sIgA-mediated immune exclusion manifests as elevated fecal sIgA while fecal calprotectin and stool white blood cells remain completely within normal ranges.

Bottom line

Food antigen exposure or mild mucosal irritation can elevate fecal sIgA as an adaptive defense mechanism while fecal calprotectin and stool white blood cells remain normal, distinguishing uncomplicated mucosal reactivity from active, neutrophil-driven tissue inflammation.